July 1, 2025 — Cognito Therapeutics announced the completion of enrollment in the HOPE pivotal trial evaluating its Spectris neuromodulation system for Alzheimer’s disease. The randomized, double-blind, sham-controlled study enrolled 670 patients across 70 U.S. sites, marking the largest medical device trial focused solely on Alzheimer’s patients.
Spectris delivers proprietary gamma frequency light and sound stimulation to evoke brain oscillations disrupted in Alzheimer’s, aiming to slow disease progression. Following HOPE, a 12-month open-label extension study will assess long-term effects.
“Completing enrollment is a major step toward delivering better treatment options for neurodegenerative diseases,” said Christian Howell, CEO of Cognito. Results are expected to build on positive data from last month’s OVERTURE study.
Follow MEDWIRE.AI for neurology and CNS device updates.
